Ovarian Cancer M25-709 FLORENZA
Study details
View study details on clinicaltrials.gov.
Locations
- Santa Barbara
Clinical trial FAQs
Information for patients and study volunteers, including frequently asked questions.
A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer
Email us to enroll
Related clinical trials
View all clinical trials- Clinical trial
Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB
FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.
Status: Open to Enrollment
- Clinical trial
Adjuvant Ovarian Cancer NRG-GY036
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
Status: Open to Enrollment
- Clinical trial
Advanced Ovarian Cancer Catalina-2
Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)
Status: Open to Enrollment
- Clinical trial
Advanced Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer GOG-3115
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Ovarian Cancer DESTINY-Ovarian01
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)
Status: Open to Enrollment